viking oral glp 1 BioWorld Viking strikes $150m deal to
Description
("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in a poster presentation at ObesityWeek 2025, the annual meeting of The Obesity Society
Important update for our community The White House recently announced that TrumpRX will be lowering the cost of brand-name Ozempic and Wegovy to $350/month
Check pricing here.
Have you or a loved one taken Invokana a medication for Type 2 Diabetics
Obesity has become a major global health crisis impacting every corner of the world, with some of the most rapid increases in prevalence seen in low- and middle-income countries
